Giant Fold Gastritis Induced by Epoprostenol Infusion in Patients With Pulmonary Arterial Hypertension

被引：3

作者：

Miura, Yohei ^{[1
]}

Kataoka, Masaharu ^{[3
]}

Chiba, Tomohiro ^{[2
]}

Inami, Takumi ^{[1
]}

Yoshino, Hideaki ^{[1
]}

Satoh, Toru ^{[1
]}

机构：

[1] Kyorin Univ, Sch Med, Dept Internal Med 2, Div Cardiol, Tokyo, Japan

[2] Kyorin Univ, Sch Med, Dept Pathol, Tokyo, Japan

[3] Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan

来源：

CIRCULATION JOURNAL | 2018年 / 82卷 / 10期

关键词：

Epoprostenol; Giant fold gastritis; Pulmonary arterial hypertension; Stomach barium examination; THERAPY;

D O I：

10.1253/circj.CJ-18-0349

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.

引用

页码：2676 / 2677

页数：2

共 50 条

[41] Epoprostenol/tozinameranAcute exacerbation of pulmonary arterial hypertension and no therapeutic response
Reactions Weekly, 2024, 1993 (1) : 72 - 72
[42] Thyroid Gland in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
Abughazaleh, S. J.
Safdar, Z.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[43] Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension
Simonneau, Gerald
Rubin, Lewis J.
Galie, Nazzareno
Barst, Robyn J.
Fleming, Thomas R.
Frost, Adaani
Engel, Peter
Kramer, Mordechai R.
Serdarevic-Pehar, Marjana
Layton, Gary R.
Sitbon, Olivier
Badesch, David B.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (07): : 689 - 697
[44] Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension
Reisbig, KA
Coffman, PA
Floreani, AA
Bultsma, CJ
Olsen, KM
ANNALS OF PHARMACOTHERAPY, 2005, 39 (04) : 739 - 743
[45] Thrombocytopenia during epoprostenol infusion for primary pulmonary hypertension: Is there a relation to dose?
Mow, B
Kumar, S
Monahan, KH
Severson, CJ
Schroeder, G
Fonseca, R
McGoon, MD
Phyliky, RL
BLOOD, 1998, 92 (10) : 87B - 87B
[46] Primary pulmonary hypertension treated with short-term epoprostenol infusion
Shiota, Y
Mikawa, Y
Arikita, H
Nakashima, T
Horita, N
Hiyama, J
Ono, T
Yamakido, M
INTERNAL MEDICINE, 2003, 42 (09) : 824 - 826
[47] Pulmonary hypertension in systemic lupus erythematosus treatment with intermittent epoprostenol infusion
Kong, SO
Badsha, H
Thumboo, J
Feng, PH
ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S242 - S242
[48] Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma
Farber, HW
Graven, KK
Kokolski, G
Korn, JH
JOURNAL OF RHEUMATOLOGY, 1999, 26 (05) : 1195 - 1196
[49] Epoprostenol-induced pulmonary vasodilatation in patients with pulmonary hypertension measured by electrical impedance tomography
Smit, HJ
Noordegraaf, AV
Roeleveld, RJ
Bronzwaer, JGF
Postmus, PE
de Vries, PMJM
Boonstra, A
PHYSIOLOGICAL MEASUREMENT, 2002, 23 (01) : 237 - 243
[50] Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension
Satoh, Mari
Aso, Keiko
Nakayama, Tomotaka
Saji, Tsutomu
ENDOCRINE JOURNAL, 2017, 64 (12) : 1173 - 1180

← 1 2 3 4 5 →